Hioroki Shirai PhD

Hiroki Shirai, Ph.D., Executive Fellow, Modality Research Laboratories, Astellas Pharma, Inc. 1990-2002; Tanabe Seiyaku Co Ltd. (1995-97; visiting scientist at Prof. Haruki Nakamura’s lab. at Biomolecular Engineering Research Institute, and 2000-01; visiting scientist at Prof. Tom Blundell’s lab., department of biochemistry, Univ. of Cambridge). 2002 May- Sept.; Riken Yokohama Institute. 2002Oct-05; Yamanouchi Pharmaceutical Co. Ltd, 2005-present; Astellas Pharma Inc. (2012-present; executive fellow.) 2014-present; board of protein science society of Japan. 2015-present; board of next gen. supercomputer PJ at the ministry of education, culture, sports science and technology, Japan. His major is protein engineering and informatics for drug discovery. Thanks to the experiences of in silico analysis of CDR-H3 structures, he set up high-resolution antibody modelling technology which proved competitive at Antibody modelling assessment II (AMA-II) (2014). He introduced a new concept of “design-ability” at PEGS-Europe (2015).